Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a second‐line treatment for Japanese patients with metastatic colorectal cancer
Tadamichi Denda(Chiba Cancer Center), Takayuki Yoshino(University of Tsukuba), Takeo Sato(Kitasato University), Hirofumi Fujii(Jichi Medical University), Claire Brillac(Sanofi (France)), Fumio Nagashima(Kyorin University), Kentaro Yamazaki(Shizuoka Cancer Center), Toru Sasaki(Tokyo Medical University), Michio Itabashi(Tokyo Women's Medical University), Shin Takahashi(Institute of Aging), Takeshi Kajiwara(Shikoku Cancer Center), Yoshito Komatsu(Hokkaido University Hospital), Taito Esaki(National Hospital Organization Kyushu Cancer Center), Eiji Oki(Kyushu University), Naotoshi Sugimoto(Osaka International Cancer Institute), Samira Ziti‐Ljajic(Sanofi (France)), Takashi Ura(Aichi Cancer Center), Daisuke Sakai(Osaka International Cancer Institute), Toshikazu Moriwaki(University of Tsukuba Hospital), Tetsuya Hamaguchi(National Cancer Center Hospital East), Yoshinori Sunaga(Sanofi (Japan)), Satoshi Otsu(Oita University Hospital), Takako Eguchi Nakajima(St. Marianna University School of Medicine)
Cited by 39
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k